Table 2 Hazard ratios (HR) comparing nicametate with aspirin on cerebrovascular death in stroke patients using time-dependent Cox model.
From: Impacts of treatments on recurrence and 28-year survival of ischemic stroke patients
Univariate model a | Multivariable model b | |||||
|---|---|---|---|---|---|---|
Crude HR (95% CI) | p-value | Adjusted HR (95% CI) | p-value | |||
Treatment | ||||||
Aspirin | 1.00 | 1.00 | ||||
Nicametate | 0.66 | (0.41–1.02) | 0.06 | 0.63 | (0.41–0.97) | 0.04 |
Stroke recurrence | ||||||
Non-recurrence | 1.00 | 1.00 | ||||
Recurrence | 2.53 | (1.48–4.33) | < 0.01 | 3.01 | (1.73–5.23) | < 0.01 |
Age | ||||||
< 65 | 1.00 | 1.00 | ||||
≧65 | 2.16 | (1.40–3.32) | < 0.01 | 2.26 | (1.46–3.51) | < 0.01 |
Sex | ||||||
Female | 1.00 | 1.00 | ||||
Male | 1.60 | (1.02–2.51) | 0.04 | 1.66 | (1.04–2.63) | 0.03 |
Creatinine (mg/dl) | ||||||
≤ 1.4 | 1.00 | 1.00 | ||||
> 1.4 | 1.78 | (0.98–3.21) | 0.06 | 1.52 | (0.83–2.77) | 0.18 |
Glucose (mg/dl) | ||||||
< 100 | 1.00 | 1.00 | ||||
≧100 | 1.26 | (0.81–1.94) | 0.31 | 1.49 | (0.95–2.32) | 0.08 |
TG (mg/dl) | ||||||
< 150 | 1.00 | – | ||||
≧150 | 0.85 | (0.56–1.29) | 0.44 | – | ||
TC (mg/dl) | ||||||
< 200 | 1.00 | – | ||||
≧200 | 0.77 | (0.52–1.17) | 0.22 | – | ||
SBP (mmHg) | ||||||
< 140 | 1.00 | – | ||||
≧140 | 1.00 | (0.99–1.01) | 0.77 | – | ||
DBP (mmHg) | ||||||
< 90 | 1.00 | – | ||||
≧90 | 0.99 | (0.98–1.01) | 0.77 | – | ||
